Abstract: Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist.

Abstract: Magnetosomes for use in a sequential laser radiation medical treatment, wherein the magnetosomes are administered to a body part of an individual. In a first step, the magnetosomes are irradiated by a laser radiation, and in a second step, the magnetosomes are irradiated by a laser radiation of lower power than in the first step or no laser irradiation of the magnetosomes is performed. The sequence of the first step and second step is repeated at least once.

Abstract: This disclosure relates to particles, compositions, methods of making, and methods of use thereof.

Abstract: A melt processed viral nanoparticle construct for delivery of virus or virus-like particles to a site of interest includes a degradable polymer matrix and a plurality of virus or virus-like particles encapsulated within the degradable polymer matrix. The nanoparticle construct upon administration to the site of interest providing a sustained release of the virus or virus-like particles and/or nanoparticles upon degradation of the polymer matrix.

Abstract: The invention generally relates to transmucosal administration systems for administering quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route. The present invention more specifically relates to methods of treatment for Duchenne Muscular Dystrophy that includes administering to a patient a dose in the form of one or more transmucosal administration systems.

Abstract: An adhesive patch is described that contains an improved release liner for the treatment of various skin conditions.

Abstract: The patch of the present invention comprises a backing layer and an adhesive layer laminated on the backing layer, wherein a water vapor transmission rate of the backing layer is 400 g/m2·24 hours or more, and the adhesive layer comprises a drug, dimethylsulfoxide and an adhesive. Such a patch does not fall off easily even after long wear.

Abstract: The present invention relates to the novel combination of pongamia oil and 4-t-butylcyclohexanol, and to the uses thereof in the fields of cosmetics and dermatology to combat redness. More specifically, the present invention relates to the cosmetic use of a composition comprising said combination to combat rosacea.

Abstract: The present disclosure provides compositions comprising cannabidiol and methods of making and using same.

Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV and the methods for the treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain.

Abstract: The present invention is directed to methods and uses of a series of compounds and compositions comprising the same for treating diseases, disorders and/or conditions related to fertility and preserving same and conditions related to same. In some aspects, the compounds and or compositions as herein described promote, improve, recover or restore fertility in a subject in need thereof, including in male and/or female subjects. Such methods/uses include promoting, enhancing or improving fertility-associated cell or tissue yield as part of an in vitro fertilization protocol.

Abstract: A method of administering a drug formulation comprising intranasally administering a nanoparticle composition of an effective amount of a subanesthetic racemic mixture of ketamine comprising equal amounts of R(?)ketamine and S(+)ketamine, using a chitosan or pectin excipient with an effective amount of pharmacologically acceptable salt thereof.

Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.

Abstract: The disclosure herein relates to the innovative epinephrine formulations in aqueous solution of medicinal products that enhance the physicochemical stabilities of epinephrine and extend the product shelf life. In some instances, the formulations comprise epinephrine or a salt thereof, a complexing agent, and a “non-sulfite” antioxidant. The epinephrine formulations substantially demonstrated the superior physicochemical stabilities to conventional sulfite formulation of commercial medications currently available. In some instances, sulfite-free formulations further provide further benefit (e.g., safety benefits) to sulfite-sensitive patients. The compositions, methods for preparing the formulations, and methods of using the same (e.g., in the treatment of anaphylaxis) are also provided.

Abstract: Methods and compositions for treating Attention-deficit/hyperactivity disorder are provided which include administering to a patient in need thereof captodiamine or a pharmaceutically acceptable salt thereof.

Abstract: A solid oral dosage form comprising therapeutically effective amounts of acetaminophen and a non-steroidal anti-inflammatory drug (NSAID) as active ingredients. The dosage form may contain binder material to cohesively bind the ingredients. The dosage form may further comprise a disintegrant to ensure effective disintegration in the gastrointestinal tract. For example, the solid oral dosage form may be a single tablet that contains about 1,000 mg of acetaminophen and about 400 mg of ibuprofen. In another example, the solid oral dosage form may be a single tablet that contains about 650 mg of acetaminophen and about 400 mg of ibuprofen. This invention may be particularly suitable in the management of dental pain.

Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from paracetamol and propacetamol.

Abstract: Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating myeloid malignancies. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), and/or myelodysplastic syndrome (MDS).

Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Abstract: Providing an orally deliverable composition that includes iron and avenanthramide 2c increases the bioavailability of the iron in the composition. Avenanthramide 2c can be delivered in an effective amount by selecting ingredients high in avenanthramide 2c or increasing the bioaccessibility of avenanthramide 2c in certain ingredients before including them in the composition.

Abstract: A composition for use in the therapy of veisalgia. The composition comprises at least one sugar compound, mineral salts, at least one compound for cell protection, at least one compound for promoting cell function, at least one compound for promoting detoxification, at least one neurotransmitter, at least one trace element, folic acid, optionally further trace elements and optionally a stimulating alkaloid. The composition contains no analgesic. A dosage of the composition, a therapy kit and an analgesic are also disclosed.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and progressive conditions such as Parkinson's disease. Such conditions may be caused by disease, be symptoms or sequelae of disease. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

Abstract: Disclosed is a composition for preventing or treating hepatitis containing a monoacetyl diacylglycerol compound which not only can effectively prevent and treat hepatitis, but also is safe without any side effects when used. The composition contains a monoacetyl diacylglycerol compound represented by Chemical Formula 1 in the specification as an active ingredient. In Chemical Formula 1 of the specification, R1 and R2 are each independently a fatty acid group having 14 to 22 carbon atoms.

Abstract: In this study, we capitalized on the antimicrobial property and low oral bioavailability of known salicylanilide anthelmintics (closantel, rafoxanide, niclosamide, oxyclozanide) to target the gut pathogen. The anthelmintics displayed excellent potency against C. difficile strains 630 and 4118 (with MIC values as low as 0.06-0.13 ?g/mL for rafoxanide) via a membrane depolarization mechanism, interestingly, closantel, rafoxanide and compound 8 were bactericidal against logarithmic- and stationary-phase cultures of the BI/NAP1/027 strain 4118. Further evaluation of the salicylanilides showed their preferential activity against Gram-positive over Gram-negative bacteria. Moreover, the salicylanilides were non-hemolytic and were non-toxic to mammalian cell lines HepG2 and HEK 293T/17 within the range of their in vitro MICs and MBCs. The salicylanilide anthelmintics exhibit desirable bactericidal and pharmacokinetic properties and are amenable to repositioning as anti-C. difficile agents.

Abstract: Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).

Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.

Abstract: The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.

Abstract: Embodiments of the disclosure concern methods and compositions that include a substrate that comprises at least one fluorophore in sufficient amounts and delivery of the substrate to an individual in need of treatment. In specific embodiments, a sufficient amount of fluorescein is provided on a contact lens, for example, and delivered to an individual suffering from blepharospasm.

Abstract: Methods of treating a methicillin-resistant Staphylococcus aureus (MRSA) infection or a Staphylococcus pseudintermedius infection in subject in need thereof are provided, the methods comprising administering to the subject an effective amount of a topical gel composition comprising vitamin E d-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS); and at least one lipophile. Compositions, methods of manufacture, and methods of use in inhibiting microbial growth are also provided.

Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.

Abstract: A method for treating Alzheimer's disease (AD) by administering to an AD patient a PKC activator, such as a bryostatin-1, without administering a NMDA receptor antagonist, such as memantine.

Abstract: Antioxidative stress compositions, methods of using antioxidative stress composition and methods of preparing antioxidative stress composition compositions are described. The antioxidative stress compositions may be chemopreventive and/or immunomodulatory. Resveratrol, genistein, ellagic acid, curcumin and quercetin may be included in the antioxidative stress composition compositions individually or in any combination.

Abstract: A new indication for the Warfarin family of drugs is described. In patients suffering from chronic periodontitis, continued systemic medication with Warfarin causes a significant reduction in their chronic periodontitis, including reduction in the frequency and severity of gingival inflammation occurrences, and significant decrease in the buildup of dental plaque and tartar. Delivery of Warfarin or its analogs directly to the oral fluid using toothpaste, mouthwash, chewing gum, dental floss, toothbrush, pill, and other forms are described to reduce chronic periodontitis, dental plaque, and dental tartar.

Abstract: The present invention found that lasofoxifene is an antagonist of ER-?36. It not only inhibits the growth of ER-?36 positive lung, colon and gastric cancers, and also it can inhibit the growth of acquired or de novo tamoxifen-resistant MCF-7 cells. Our finding also provides methods and compositions for treating cancer comprising lasofoxifene alone or in combination with at least one other agent selected from the group consisting of gefitinib and/or trastuzumab or functional equivalent thereof, and an inhibitor in hormonal or epidermal growth factor signal transduction pathways.

Abstract: The present invention provides compounds and methods for mitigating a clinical condition associated with a neurodegenerative disease or a locomotor dysfunction in a subject. In one particular aspect, the invention relates to compounds and methods for reducing TDP-43 aggregation or toxicity in a subject.

Abstract: Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.

Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.

Abstract: The invention provides a compound for use in the treatment of T-Cell Acute Lymphoblastic Leukaemia (T-ALL), the compound having the formula (1): or being a pharmaceutically acceptable salt thereof; wherein: n is 0, 1 or 2; Ar1 is selected from an optionally substituted phenyl, pyridyl, thienyl and furanyl; Q1 is selected from C(?O), S(?O) and SO2; A is absent or is NR2; R1 is selected from: hydrogen; an optionally substituted C1-6 non-aromatic hydrocarbon group; and optionally substituted 3- to 7-membered non-aromatic carbocyclic and heterocyclic rings containing one or two heteroatom ring members selected from O, N and S, and bridged bicyclic heterocyclic rings of seven to nine ring members of which one or two are nitrogen atoms, the carbocyclic and heterocyclic rings and bridged bicyclic heterocyclic rings; R2 is selected from hydrogen and C1-4 alkyl; or NR1R2 forms an optionally substituted 4- to 7-membered non-aromatic nitrogen-containing heterocyclic ring optionally containing a second hete

Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.

Abstract: The present invention relates to a method for reducing CD95-mediated cell motility. To identify chemicals disrupting CD95/PLC?1 interaction, the inventors screened a chemical library of EMA/FDA-approved molecules against a protein-fragment complementation assay (PCA) monitoring the binding of CD95 to PLC?1. From this screen, five chemical molecules showed the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to a method for reducing CD95-mediated cell motility, comprising administering the subject with at least one compound selected from the group consisting of HIV-protease inhibitors (e.g. ritonavir), diflunisal, anethole, rosiglitazone and daunorubicin.

Abstract: Provided herein, inter alia, are compositions and methods for generating a immune response in an individual and/or inducing the expression of neoantigens on the surface of abnormal (such as proliferative) cells via promotion of premature termination codon (PTC) read-through of messenger RNAs (mRNAs) bearing PTCs.

Abstract: The present disclosure relates to pharmaceutical compositions and methods for inhibiting Pde, promoting hair growth, and treating hair growth disorders, such as baldness or alopecia.

Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (A) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.

Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.

Abstract: Various aspects and embodiments disclosed herein relate generally to the modelling, treatment, reduction of resistance to the treatment, prevention, and/or diagnosis of diseases characterized by the formation of cancers. Embodiments include methods of treating cancer, comprising the steps of: providing a patient diagnosed with cancer with a therapeutic regime that includes at least one therapeutically effective dose of at least one agent that reduces the activity of at least one DNA damage/repair pathway. Other embodiments include methods of treating cancer, comprising the steps of: treating a patient diagnosed with cancer with a combination of therapeutic agents that includes at least one therapeutically effective anti-cancer agent and at least one compound that reduces the activity of at least one DNA damage/repair pathway.

Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.

Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.

Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol or a pharmaceutically-acceptable salt thereof.

Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include inhibitors or antagonists of leukotriene A4 hydrolase (“LTA4H”) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.